Dacomitinib as a retreatment for advanced non‐small cell lung cancer patient with an uncommon EGFR mutation

In non‐small cell lung cancer (NSCLC), uncommon epidermal growth factor receptor (EGFR) mutations are mutations other than Ex19 deletion and Ex21 L858R, which are common mutations highly sensitive to EGFR‐tyrosine kinase inhibitors. Afatinib, a second‐generation EGFR‐tyrosine kinase inhibitor, has b...

Descripción completa

Detalles Bibliográficos
Autores principales: Morita, Ayako, Hosokawa, Shinobu, Yamada, Kotaro, Umeno, Takahiro, Kano, Hirohisa, Kayatani, Hiroe, Shiojiri, Masaaki, Sakugawa, Makoto, Bessho, Akihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046035/
https://www.ncbi.nlm.nih.gov/pubmed/33651475
http://dx.doi.org/10.1111/1759-7714.13897

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046035/
https://www.ncbi.nlm.nih.gov/pubmed/33651475
http://dx.doi.org/10.1111/1759-7714.13897

Ejemplares similares